AUR-AD9G-TTM2-A-1-1-R-A542-39
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.540
- BILE_ACID_METABOLISM+0.480
- FATTY_ACID_METABOLISM+0.360
- IL6_JAK_STAT3_SIGNALING+0.260
- COAGULATION+0.250
- HEME_METABOLISM+0.220
- PEROXISOME+0.200
- KRAS_SIGNALING_DN+0.190
- ADIPOGENESIS+0.140
- PANCREAS_BETA_CELLS+0.140
Top 10 suppressed
- MYC_TARGETS_V1-0.550
- E2F_TARGETS-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- DNA_REPAIR-0.430
- MYC_TARGETS_V2-0.410
- G2M_CHECKPOINT-0.360
- PROTEIN_SECRETION-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- ANGIOGENESIS-0.290
- NOTCH_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0217_T2_RNA | — | C | 0.800 |
| 2 | SRR4195694 | — | — | 0.774 |
| 3 | SRR12696784 | — | — | 0.771 |
| 4 | TCGA-O1-A52J-01A-11R-A262-07 | — | cohortA1 | 0.741 |
| 5 | TCGA-55-1592-01A-01R-0946-07 | — | cohortA1 | 0.738 |
| 6 | SRR975601 | — | — | 0.734 |
| 7 | C3L-02967 | — | cohortA2 | 0.734 |
| 8 | AUR-AFE9-TTM4-A-1-1-R-A742-41 | — | C | 0.728 |
| 9 | TCGA-62-A470-01A-11R-A24H-07 | — | cohortA3 | 0.716 |
| 10 | SJEPD011_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.712 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.540 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.480 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |